Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.43 – $1.36
14% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.8M | $19.5M | $21.6M | $20.1M | $19.4M | $17.0M | $9.5M | $9.0M |
| Cost of revenue | $12.1M | $13.3M | $14.9M | $14.8M | $14.5M | $11.9M | $7.0M | $6.1M |
| Gross profit | $5.7M | $6.2M | $6.7M | $5.4M | $4.9M | $5.1M | $2.5M | $2.9M |
| Gross margin | 32.0% | 31.7% | 30.9% | 26.6% | 25.2% | 29.8% | 26.5% | 32.3% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $1.1M | $1.7M | $2.2M | −$3.9M | $1.2M | $1.1M | −$1.3M | −$637.7K |
| EBITDA | $1.2M | $2.3M | $2.4M | −$3.8M | $1.2M | $1.3M | −$1.1M | $134.8K |
| Net income | $1.3M | $2.1M | $2.1M | −$2.1M | $1.0M | $1.3M | −$777.6K | −$100.5K |
| Net margin | 7.2% | 10.7% | 9.5% | -10.4% | 5.2% | 7.7% | -8.2% | -1.1% |
| EPS (diluted) | 0.06 | 0.09 | 0.09 | -0.09 | 0.04 | 0.06 | -0.03 | -0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $12M | $0.07 | $0.07–$0.07 | 1 |
| 2027 | $13M | $0.11 | $0.11–$0.11 | 1 |
Forward consensus · source: Financial Modeling Prep
PHARM-BIO SERV INC
No one on the platform currently holds PBSV.
No tracked institution reports a position in PBSV as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-02-27 | $0.0750 | 2026-03-20 |
| 2025-02-28 | $0.0750 | 2025-03-20 |
| 2024-01-29 | $0.0750 | 2024-02-15 |
No one on the platform has traded PBSV yet.
| $8M |
| — |
| PAXHPreAxia Health Care Payment Systems Inc. | $0.22 | +0.00% | $4M | — |
| SPLTFSpotLite360 IOT Solutions, Inc. | $0.08 | +0.00% | $8M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 1.3× sales vs its 1.3× historical median P/S.
Fair value ≈ $0.54 · price $0.56 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.